Meloxicam in mobilization with Colony stimulating factor (G-CSF) will improve mobilization rates in patients undergoing mobilization for autologous stem cell transplantation.
Phase 2
- Conditions
- Health Condition 1: null- Autologous stem cell transplantation
- Registration Number
- CTRI/2014/06/004671
- Lead Sponsor
- Investigator Initiated Study
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 50
Inclusion Criteria
1. Adult patients > 18 years undergoing stem cell mobilization for autologous SCT.
2. No previous harvesting
3. Willing to give consent for the study
Exclusion Criteria
1. Children 18 years of age
2. Normal healthy donors
3. Patients with past history/active duodenal or peptic ulcer
4. Patients with pre-existing coronary artery disease or renal failure
5. Patients on Losartan, Lisinopril or Captopril
6. Patients with history of allergy to NSAIDs
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study if the addition of meloxicam to the standard protocol of G-CSF mobilization will improve the first day mobilization rates (target cell dose of 5 x 106 CD34/kg) in patients undergoing mobilization for autologous stem cell transplant.Timepoint: Post Day 7 of Meloxicam with GCSF
- Secondary Outcome Measures
Name Time Method 20 days post transplantTimepoint: 20 days post transplant